Welcome to our dedicated page for Cooper SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CooperCompanies, Inc. (Nasdaq: COO) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its operations as a global medical device company. These SEC filings cover its two business units, CooperVision and CooperSurgical, and include information on revenue, segment performance, margins, cash flow, and significant corporate actions.
On this page, you can review annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which typically present consolidated financial statements, segment data for CooperVision and CooperSurgical, discussions of non‑GAAP measures, and explanations of items such as acquisition and integration‑related charges, business optimization charges, and product line exits. These filings also describe how the company defines and uses metrics like constant currency revenue growth, organic revenue growth, and free cash flow.
Current reports on Form 8‑K provide timely updates on material events, such as quarterly earnings releases, changes in executive responsibilities, and governance developments. For example, recent 8‑K filings have addressed the reporting of quarterly financial results and the assumption of principal accounting officer responsibilities by the company’s Chief Financial Officer. Proxy statements referenced in these filings contain biographical and governance information about directors and senior executives.
Stock Titan enhances access to COO filings by offering AI‑powered summaries that explain key sections of lengthy documents in plain language. Real‑time updates from EDGAR ensure that new 10‑K, 10‑Q, and 8‑K filings appear quickly, while insider transaction reports on Form 4, when available, can be used to monitor trading activity by officers and directors. These tools help users navigate CooperCompanies’ regulatory disclosures more efficiently and understand the financial and governance details that shape the company’s performance.
Cooper Companies director Robert S. Weiss reported routine equity compensation activity. On April 1, 2026, he exercised 3,654 Restricted Stock Units, receiving the same number of common shares at $0.00 per share, bringing his direct common stock holdings to 292,599 shares.
On the same date, he was granted 3,779 new Restricted Stock Units, each tied to an equal number of common shares and subject to future vesting or forfeiture. He also reports 257,860 common shares held indirectly by the Robert and Marilyn Weiss Trust dated 5/17/06, for which he and his spouse serve as co‑trustees. No open‑market purchases or sales were reported.
Cooper Companies director Maria Rivas reported routine equity compensation changes. She exercised restricted stock units into 3,322 shares of common stock on April 1, 2026, and now holds 3,322 shares directly. She also received a new grant of 3,779 restricted stock units scheduled to vest on April 1, 2027. In addition, 11,141 common shares are held indirectly through The Maria Rivas Trust Dated June 24, 2013, where she serves as sole trustee.
Cooper Companies director Colleen Jay reported equity compensation activity involving restricted stock units and common shares. On April 1, 2026, 3,322 restricted stock units were exercised and converted into 3,322 shares of common stock. On the same date, Jay also received a new grant of 4,157 restricted stock units, which may vest or be forfeited and has no expiration date. Following these transactions, Jay directly owned 39,907 shares of common stock and held 4,157 restricted stock units.
Cooper Companies director Barbara Carbone reported routine equity compensation activity. On April 1, 2026, she exercised 3,050 Restricted Stock Units, converting them into 3,050 shares of Common Stock at a stated price of $0.00 per share, reflecting non-cash vesting rather than a market purchase.
On the same date, she also received a new grant of 3,779 Restricted Stock Units, each representing a right to acquire one share of Common Stock. The award has no expiration date; the units will either vest or be forfeited over time. Following these transactions, she directly holds 3,050 shares of Common Stock and 3,779 Restricted Stock Units.
Rosebrough Walter M Jr reported acquisition or exercise transactions in this Form 4 filing.
COOPER COMPANIES, INC. director Walter M. Rosebrough Jr received a grant of 3,779 Restricted Stock Units on April 1, 2026 as equity compensation. Each unit represents one share of common stock.
The RSUs are scheduled to vest on April 1, 2027 and have no expiration date; they will either vest or be forfeited. Following this award, he holds 3,779 RSUs directly, and there were no open-market purchases or sales in this filing.
COOPER COMPANIES, INC. director Teresa S. Madden reported routine equity compensation activity involving restricted stock units and common shares. On April 1, 2026, she exercised 3,322 restricted stock units into 3,322 shares of common stock at $0.00 per share, increasing her direct common stock holdings to 15,679 shares.
On the same date, she received a new grant of 3,779 restricted stock units, each representing one share of common stock, scheduled to vest on April 1, 2027. A related footnote explains that this award has no expiration date and that the units will either vest or be forfeited, underscoring their service-based nature rather than being a market transaction.
Cooper Companies director Cynthia L. Lucchese reported compensation-related equity activity. On April 1, 2026, she exercised 3,322 Restricted Stock Units, acquiring the same number of common shares at a stated price of $0.00 per share. She also received a new grant of 3,779 Restricted Stock Units, which are scheduled to vest on April 1, 2027. After these transactions, she holds 12,767 shares of Cooper Companies common stock directly. A footnote explains the RSU award has no expiration date and that units will either vest or be forfeited.
Cooper Companies director Lawrence Erik Kurzius reported equity compensation activity involving restricted stock units and common stock. He exercised 3,322 Restricted Stock Units into 3,322 shares of Common Stock at a stated price of $0.00 per share, converting a derivative award into stock ownership.
He also received a new grant of 3,779 Restricted Stock Units, which have no expiration date and will either vest or be forfeited according to the award terms. Following these transactions, he directly owns 11,099 shares of Common Stock and holds 3,779 Restricted Stock Units, reflecting routine compensation-related acquisitions rather than open-market buying or selling.
Cooper Companies, Inc. ownership filing amended: The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0%. The amendment explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with disaggregated reporting by subsidiaries. filing signed March 26, 2026.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.